Towards ‘Eternal Youth’ of cardiac and skeletal muscle

Magdi Yacoub1, Ahmed ElGuindy2,*

INTRODUCTION
The dream of eternal youth, exemplified throughout history by several examples such as the Epic of Gilgamesh in ancient Sumeria (Figure 1) in which the King of Uruk searches for a plant to restore youth, and the story of Dorian Gray in Oscar Wilde’s classical novel (Figure 2), has captured the imagination of mankind, and continues to be a major target for research. This is stimulated by the fact that the recent increase in life expectancy has resulted in a massive increase in the percentage of “ageing” individuals in the community (Figure 3). Ageing affects several organ systems, with two of the most crippling, involving cardiac and skeletal muscles. In this article we review the recent developments in these two areas.

REVERSING AGEING CARDIAC MUSCLE
Advancing age results in myocardial diastolic dysfunction, which can cause heart failure with preserved ejection fraction (HFrEF), currently thought to be as prevalent as heart failure with reduced ejection fraction (HFrEF). In stark contrast to the latter, where the use of beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and aldosterone antagonists have resulted in remarkable reductions in mortality, no evidence-based therapies exist to treat HFrEF to date1–7. Compared to HFrEF, HFrEF patients are older, more commonly women, and have a higher prevalence of hypertension, obesity, atrial fibrillation, and noncardiac comorbidities8. Among elderly women, HFrEF comprises almost 90% of newly diagnosed heart failure cases 9. The prevalence of HFrEF has been rising steadily over the past two decades at a rate of approximately 1% per year, in contrast to that of HFrEF, which has remained unchanged over the same period1. At this rate, and with the current population ageing trends, it is expected that HFrEF will represent the dominant heart failure phenotype in the near future.

The molecular pathogenesis of HFrEF has not been adequately defined, but it is now evident that diastolic dysfunction is not the only underlying abnormality10,11. Other mechanisms including ageing12, skeletal muscle dysfunction13–16, inflammation17, neuroendocrine and renal dysfunction18–20, chronotropic incompetence21, right ventricular dysfunction22, abnormal ventricular-arterial coupling23,24, and endothelial dysfunction25,26 have been implicated. Changes affecting the myocardium, namely impaired relaxation and increased stiffness, are cornerstone to the development of HFrEF. Recent experiments utilizing chronic parabiosis, figure, whereby the circulations of two mice are joined (Figure 4a) have thrown new light on the mechanisms of HFrEF in old animals. Loffredo and colleagues, conducted a series of elegant experiments in mice with age related cardiac hypertrophy and failure, analogous to that in humans27. When joined to young animals (heterochronic parabiosis) for a period of four weeks, the old animals showed regression of cardiac hypertrophy without influencing the structure of the joined young animal heart (Figure 4b). The structural and functional reverse remodeling observed in the older hearts exposed to heterochronic parabiosis was associated with decrease in the classical molecular markers of hypertrophy and wall stress such as ANP and BNP, with increase in sarcoplasmic endoplasmic reticulum Ca2+ a (SERCA 2a) known to be decreased in diastolic dysfunction28,29,30,31.
In an attempt to explore the mechanisms responsible and the possible therapeutic implications, the authors conducted an extensive search for the circulating substance or substances responsible for the observed changes. Utilizing broad-scale proteomics analysis using aptamer-based technology, they identified several candidate molecules, including growth-differentiation factor 11 (GDF11). This growth factor belongs to the transforming growth factor-β (TGF-β) superfamily of growth and differentiating factors, which includes the TGF-βs, activins and bone morphogenetic proteins. TGF-β superfamily is known to regulate cell growth and differentiation as well as cell death. The actions and specificity of members of the TGF-β superfamily secreted proteins are transmitted to the nucleus.

Figure 1. Map of Ancient Mesopotamia (a). The arrow points to the city of Uruk in Sumeria. Poem of the Epic of Gilgamesh – 11th tablet (British Museum) (b). The poem (circa 2100 BC), is often regarded as the first great work of literature. The second half of the epic describes the long and perilous journey of Gilgamesh, King of Uruk, in search of eternal life.
Figure 2. Actor Ben Barnes starring as Dorian Gray in a 2009 British movie based on Oscar Wilde’s classical novel “The Picture of Dorian Gray” (1891).

Figure 3. Population pyramids of the less and more developed regions: 1970, 2013, and 2050 [source: UN World Population Ageing 2013].
by the Smad pathway, which acts as depressor and stimulator of transcription of a large number of relevant genes (Figure 5).

Previous work in our lab, has shown that Activin/Follistatin (another member of the TGF-β superfamily) pathway could play an important role in remodeling associated with HF as well as reverse remodeling following left ventricular assist device (LVAD) combination therapy33. Loffredo and colleagues demonstrated that the circulating levels of GDF11 decreased with age and were restored following heterochronic parabiosis. To investigate the physiologic relevance of their findings, they went on to show that GDF11 can prevent myocardial hypertrophy both in vitro and in vivo models, and that systemic administration of this substance in old animals with abnormal hearts resulted in reverse remodeling, similar to that observed following heterochronic parabiosis. As mentioned by Rando and Finkel34, these experiments suggest that Galen was right when he stated that disease was due to “bad humor”; circulating blood in this case. Taken together, these findings might have very exciting implications with regard to developing novel therapies for the ageing myocardium.
Old age is associated with diminution in skeletal muscle mass, which is crippling in more than one way, and has been shown to be associated with fractures due to falling, declining quality of life with loss of independence. In addition, it is hypothesized that it may influence heart function. The extent of loss of skeletal muscle mass has been shown to correlate inversely with survival. Evidence from experimental models has shown that the age-related decline in skeletal muscle function is related to intrinsic changes in the skeletal myoblasts as well as circulating factors, both of which can be reversed in the animal models. Skeletal muscle homeostasis and regeneration is dependent on the existence of Pax7-expressing progenitor cells on the surface of each muscle fiber. The presence of these progenitor cells is essential for muscle regeneration and maintenance of muscle mass. A decrease in the number and function of these progenitor cells with age contributes to the decline in muscle mass.

REVERSING AGEING SKELETAL MUSCLE

Old age is associated with diminution in skeletal muscle mass, which is crippling in more than one way, and has been shown to be associated with fractures due to falling, declining quality of life with loss of independence. In addition, it is hypothesized that it may influence heart function. The extent of loss of skeletal muscle mass has been shown to correlate inversely with survival. Evidence from experimental models has shown that the age-related decline in skeletal muscle function is related to intrinsic changes in the skeletal myoblasts as well as circulating factors, both of which can be reversed in the animal models. Skeletal muscle homeostasis and regeneration is dependent on the existence of Pax7-expressing progenitor cells on the surface of each muscle fiber. The presence of these progenitor cells is essential for muscle regeneration and maintenance of muscle mass. A decrease in the number and function of these progenitor cells with age contributes to the decline in muscle mass.

**Figure 5.** Mechanism of action of Growth Differentiating Factor 11 (GDF 11). GDF 11 – a ligand from the transforming growth factor β (TGF-β) superfamily – binds the extracellular domain of type I and II Ser/Thr kinase receptors. Phosphorylation of type I receptor leads to sequential phosphorylation of members of the intracellular Smad signal transduction pathway, ultimately resulting in changes to nuclear gene expression.

**Figure 6.** Association between muscle mass and survival. 12-year survival in 1413 healthy old individuals according to sex-specific quartiles of appendicular fat free mass/height. Fat free mass was measured using dual-energy X-ray absorptiometry. Sex-specific quartiles for appendicular fat free mass divided by height were calculated to account for sex differences in body composition. Quartile 1 corresponds to the lower quartile while 4 corresponds to the upper quartile. From Bunout D. et al.
normal muscle fibre. Skeletal myoblasts can be separated using single fibre cell culture technique, or cell sorter due to their unique expression of surface molecules Sca1−, CD45−, CD11B−, CXCR4+, Beta 1 integrin and other progenitor cells. Skeletal myoblasts can self renew and differentiate to myotubes which regenerate skeletal muscle (Figure 7). The number of skeletal myoblasts as well as their capacity to regenerate skeletal muscle decline with advancing age. The mechanisms responsible for this decline have been shown to be due both to inherent changes of the skeletal myoblasts, as well as due to changes in circulating factors similar to those described for the aging myocardium. With regard to the intrinsic changes, Pedro Sousa and colleagues from Barcelona showed that the aging skeletal myoblasts lose the capacity for reversible quiescence and activation which was due to down regulation of p16 ink4a. This loss of regenerative capacity of the aging myoblasts persisted even after transplantation in young rats, showing that these changes were independent of the environment. Silencing of p16 ink4a restored the functional regenerative capacity of the cells. Work by Price et al. and Tierney et al. implicated yet another pathway – JAK-STAT – and demonstrated an age-related increase in JAK-STAT signal transduction in mouse muscle suggesting

Figure 7. The effect of age on skeletal muscle regeneration. Quiescent progenitor cells (satellite cells) exist on the surface of skeletal muscle fibres. Following damage to the muscle, these cells are capable of proliferating into muscle progenitor cells - that eventually regenerate new muscle fibres - and self-renewal to replenish their own population. This capacity progressively declines with ageing.

Figure 8. Janus Kinase Signal Transducer and Activator of Transcription (JAK-STAT) pathway (left; a) and Janus, the Roman God of gates, doors, passages and endings (right; b).
that it may suppress myogenic activity. The authors went on to demonstrate that JAK-STAT inhibition promoted satellite cell expansion and rescues muscle regeneration defects in elderly and dystrophic mice using a series of in-vitro and transplant-based siRNA inhibition of JAK kinase and Stats (Figure 8).50-52

Recent work by Sinha, Richard Lee, and Amy Wagers from Harvard, using heterochronic parabiosis, showed that decline in circulating GDF11 levels is implicated in the age-related decline in skeletal muscle function.53

CONCLUSIONS AND FUTURE DIRECTIONS

New experimental work has shown, in small animal models, that cardiac and skeletal dysfunction associated with ageing can be reversible, through different mechanisms. This opens the door for concerted research in the applicability of these or other methods to large animal models and ultimately humans, bringing the dream of “eternal youth” nearer.

Acknowledgements

The authors would like to thank Dr. Hassan Kamel for producing the illustrations.

REFERENCES

[1] Owan TE, Hodge DO, Jacobsen SJ, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. 2006;355:251–259.
[2] Holland DJ, Kamath B, Ahmed SH, Manwick TH. Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-analysis. J. Am. Coll. Cardiol. 2011;57:1676–1686.
[3] ElGuindy A, Yacoub M. Review article: Heart Failure with Preserved Ejection Fraction. Glob. Cardiol. Sci. Pract. 2012;10.
[4] Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Olofsson B, Ostergren J, Cohn JN, Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–781.
[5] Cleland JGF, Tendera M, Adams J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur. Heart J. 2006;27:2338–2345.
[6] Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Verson E, Stagier C, Ptaszynska A, 1-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med. 2008;359:2456–2467.
[7] Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shah SJ, Solomon SD, Szwiter NK, Yang S, McKinlay SM, TOPCAT Investigators. Spirololactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 2014;370:1383–1392.
[8] Goldschmidt-Clermont PJ, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF, Fonarow GC. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126:66–75.
[9] Gottlieb DJ, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, Gardin JM, Rutledge JE, Boineau RC. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J. Am. Coll. Cardiol. 2000;35:1628–1637.
[10] Borlaug B, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, Redfield MM. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J. Am. Coll. Cardiol. 2010;56:845–854.
[11] Maurer MS, Hummel SL. Heart failure with a preserved ejection fraction: what is in a name? J. Am. Coll. Cardiol. 2011;58:275–277.
[12] Lakatta Eg, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation. 2003;107:346–354.
[13] Blaoua PS, Prasad A, Heinicke K, Hastings JL, Arbab-Zadeh A, Adams-Huet B, Pacini EL, Shibata S, Palmer MD, Newcomer BR, Levine BD. Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction. Eur. J. Heart Fail. 2011;13:1296–1304.
[14] Nicklas BJ, Leng I, Delbono O, Kitzman DW, Marsh AP, Hundleby WG, Lyles MF, O’Rourke KS, Dargan H, Kraus WE. Relationship of physical function to vastus lateralis capillary density and metabolic enzyme activity in elderly men and women. Aging Clin. Exp. Res. 2008;20:302–309.
[15] Haykowsky MJ, Brubaker PH, John JM, Stewart KP, Morgan TM, Kitzman DW. Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J. Am. Coll. Cardiol. 2011;58:265–274.
[16] Haykowsky MJ, Brubaker PH, Morgan TM, Kitchevsky S, Eggebeen J, Kitzman DW. Impaired aerobic capacity and physical functional performance in older heart failure patients with preserved ejection fraction: role of lean body mass. J. Gerontol. A. Biol. Sci. Med. Sci. 2013;68:968–975.
[17] Wexler D, Finkler N, Kastner M, Zierath B, Zierath J. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ. Heart Fail. 2011;4:442–452.
[18] Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundleby WG, Marburger CT, Brosnihan B, Morgan TM, Stewart KP. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA. 2002;288:2144–2150.
[19] Clarkson PB, Wheelon NM, MacFadyen RJ, Pringle SD, MacDonald TM. Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure. *Circulation*. 1996;93:2037 – 2042.

[20] Maurer MS, Burkhoff D, Fried LP, Goldtiner J, King DI, Kitzman DW. Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the Cardiovascular Health Study. *J. Am. Coll. Cardiol.* 2007;49:972 – 981.

[21] Brubaker PH, Joo KC, Stewart KP, Fray B, Moore B, Kitzman DW. Chronotropic incompetence and its contribution to exercise intolerance in older heart failure patients. *J. Cardiopulm. Rehabil.* 2006;26:86 – 89.

[22] Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. *Circulation*. 2011;124:164 – 174.

[23] Kargavci M. Combined Ventricular Systolic and Arterial Stiffening In Patients With Heart Failure and Preserved Ejection Fraction: Implications for Systolic and Diastolic Reserve Limitations. *Circulation*. 2003;107:714 – 720.

[24] Freixas M, Williams L. Ventricular-arterial and ventricular-ventricular interactions and their relevance to diastolic filling. *Prog. Cardiovasc. Dis.* 2007;49:252 – 262.

[25] Hundley WG, Bayram E, Hamilton CA, Hamilton EA, Morgan TM, Darby SN, Stewart KP, Link KM, Herrington DM, Kitzman DW. Leg flow-mediated arterial dilation in elderly patients with heart failure and normal left ventricular ejection fraction. *Am. J. Physiol. Heart Circ. Physiol.* 2007;292:H1427 – H1434.

[26] Borlaug B, Melovskov Y, Russell SD, Kessler K, Pacak K, Becker LC, Kass DA. Impaired chronicotropic and vasodilator reserve limit exercise capacity in patients with heart failure and a preserved ejection fraction. *Circulation*. 2006;114:2138 – 2147.

[27] Loffredo FS, Steinhauser ML, Jay SM, Gannon J, Pancost JR, Yalamanchi P, Sinha M, Dal’ossco C, Khong D, Shadrach JL, Miller CM, Singer BS, Stewart A, Psychogios N, Gerszten RE, Hartigan AJ, Kim MI, Serwold T, Wagers AJ, Lee RT. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. *Cell*. 2013;153:828 – 839.

[28] Frank KF, Bolck B, Brixius K, Granja E, Kranias EG, Schwinger RH. Mutation of SERCA: implications for the failing human heart. *Basic Res. Cardiol.* 2002;97(Suppl 1):172 – 178.

[29] De Monte F, Harding SE, Dec GW, Gutarra S, Rodriguez-Ubreva J, Ortet L, Ruiz-Bonilla V, Jardí M, Ballestar E, González S, Sousa-Victor P. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. *Nature*. 2014;506:304 – 305.

[30] Li M, Izpisua Belmonte JC. Ageing: Genetic rejuvenation of old muscle. *Nature*. 2014;506:304 – 305.

[31] Price FD, von Maltzahn J, Bertous AM, MacDonald TM. Inhibition of JAK-STAT signaling stimulates adult satellite cell function. *Nat. Med.* 2014;20:1174 – 1181.

[32] Tierney MT, Aydogdu T, Sala D, Malecova B, Gatto S, Pun PL, Latella L, Saccio A. STAT3 signaling controls satellite cell expansion and skeletal muscle repair. *Nat. Med.* 2014;20:1182 – 1186.

[33] Dolez JD, Olin BB. The impact of JAK-STAT signaling on muscle regeneration. *Nat. Med.* 2014;20:1094 – 1095.

[34] Romay J, Juric YC, Oh J, Khong D, Wu EY, Manohar R, Miller C, Regalado SG, Loffredo FS, Pancost JR, Hirshman MF, Lebowitz J, Shadrach JL, Cerletti M, Kim MI, Serwold T, Goodyear LJ, Rosner B, Lee RT, Wagers AJ. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. *Science*. 2014;346:649 – 652.